title: [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
abstract: We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age. In patients aged 65--74 yr treatment with dabigartan (110 mg twice daily) for 6 months was associated with ischemic stroke as frequently as warfarin therapy but less frequently than with severe hemorrhages (4.4 vs. 27.7%, p < 0.05). Clopidogrel prevented stroke as effectively as warfarin and dabigartan and was equally safe. There were no differences in the frequency of thromboembolic and hemorrhagic complications in 75-80 year-old patients given the three medications. It is concluded that dabigartan and clopidorgel may be regarded as a good alternative to warfarin for anti-platelet treatment of 65-74 year-old patients with non-valvular atrial fibrillation.
authors.forename: V I
authors.initials: VI
authors.lastname: Shevelev
authors.forename: S G
authors.initials: SG
authors.lastname: Kanorsky
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control*; D000077144:Clopidogrel; D000069604:Dabigatran; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D010975:Platelet Aggregation Inhibitors; D015091:beta-Alanine; D014859:Warfarin; D000077144:Clopidogrel; D000069604:Dabigatran; D013988:Ticlopidine